Evidence map›Paper›PMID 39273677›Full record

ArticleInternational journal of molecular sciences2024

8-Prenylgenistein Isoflavone in Cheonggukjang Acts as a Novel AMPK Activator Attenuating Hepatic Steatosis by Enhancing the SIRT1-Mediated Pathway.

Radha Arulkumar, Hee Jin Jung, Sang Gyun Noh, Hyun Woo Kim, Hae Young Chung

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Phytochemistry and Pharmacological Potential of the GenusPharmaceuticals (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Radha ArulkumarInterdisciplinary Research Program of Bioinformatics and Longevity Science, Pusan National University, Busan 46241, Republic of Korea.
Hee Jin JungDepartment of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-7212-5572
Sang Gyun NohInterdisciplinary Research Program of Bioinformatics and Longevity Science, Pusan National University, Busan 46241, Republic of Korea.
Hyun Woo KimInterdisciplinary Research Program of Bioinformatics and Longevity Science, Pusan National University, Busan 46241, Republic of Korea.
Hae Young ChungInterdisciplinary Research Program of Bioinformatics and Longevity Science, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0002-3215-8828

Funding

National Research Foundation of Korea NRF-2023R1A2C2006035
6 · The paper itself

Abstract

8-Prenylgenistein (8PG), a genistein derivative, is present in fermented soybeans (Glycine max), including cheonggukjang (CGJ), and exhibits osteoprotective, osteogenic, and antiadipogenic properties. However, the hepatoprotective effects of 8PG and its underlying molecular mechanisms remain largely unexplored. Here, we identified the high binding affinity of 8PG with AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1), which acts as a potent AMPK activator that counteracts hepatic steatosis. Notably, 8PG exhibited better pharmacokinetics with greater absorption and higher plasma binding than the positive controls for the target proteins. Moreover, 8PG exerted non-carcinogenic activity in rats and significantly increased AMPK phosphorylation. Compound C, an AMPK inhibitor, did not antagonize 8PG-activated AMPK in HepG2 cells. 8PG significantly attenuated palmitate-induced lipid accumulation and enhanced phosphorylated AMPK and its downstream target, acetyl-CoA carboxylase. Further, 8PG activated nuclear SIRT1 at the protein level, which promoted fatty acid oxidation in palmitate-treated HepG2 cells. Overall, 8PG acts as a potent AMPK activator, further attenuating hepatic steatosis via the SIRT1-mediated pathway and providing new avenues for dietary interventions to treat metabolic dysfunction-associated steatotic liver disease (MASLD).

Indexed as

AMP-Activated Protein KinasesIsoflavonesSirtuin 1AnimalsFatty LiverGenisteinGlycine maxHep G2 CellsHumansLipid MetabolismMalePhosphorylationRatsRats, Sprague-DawleySignal TransductionAMP-Activated Protein KinasesGenisteinIsoflavonesSIRT1 protein, humanSirtuin 18-prenylgenisteinAMP-activated protein kinasecheonggukjangfermented soybeanhepatic steatosissirtuin 1

Identifiers

PMID39273677
PMCPMC11395689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.